Showing results (111-120 of 330) with videos related to
Sort By:
Pageof 33
Journal of Cancer Research and Clinical Oncology|August 27, 2022
Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ studyKatharina Kolbe, Ivonne Haffner, Katrin Schierle, et al.European Journal of Cancer (Oxford, England : 1990)|December 21, 2007
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer groupEric Van Cutsem, Cornelius Van de Velde, Arnaud Roth, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 11, 2025
Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ AdenocarcinomaRob H A Verhoeven, Steven C Kuijper, Florian Lordick, et al.European Journal of Cancer (Oxford, England : 1990)|December 1, 2006
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in GermanyFlorian Lordick, Birgit Ehlken, Angela Ihbe-Heffinger, et al.Onkologie|July 4, 2008
Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-upFranz G Bader, Florian Lordick, Ulrich Fink, et al.Plos One|April 22, 2016
Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell CarcinomaVincent T Janmaat, Marco J Bruno, Suzanne Polinder, et al.The American Journal of Surgical Pathology|August 21, 2014
Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approachesEva Karamitopoulou, Svenja Thies, Inti Zlobec, et al.Radiology|March 18, 2006
Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapyAmbros J Beer, Hinrich A Wieder, Florian Lordick, et al.Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 13, 2014
Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: more than 20 years' experience at a single institutionKhashayar Fakhrian, Arif Deniz Ordu, Florian Lordick, et al.Tumori|April 25, 2015
Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapyKhashayar Fakhrian, Arif Deniz Ordu, Carsten Nieder, et al.Pageof 33